Pfizer: Leukemia, Myeloid, Acute trials
The registry lists 33 Leukemia, Myeloid, Acute studies with Pfizer as lead sponsor. 1 are open to participants now and 13 have results posted.
Phase 1 12Phase 2 12Phase 3 4Phase 4 1No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid LeukemiaRecruitingNCT05189639
- Latin American Real-world Study in Acute LeukemiaCompletedNCT05166135Results posted
- Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMMLCompletedNCT04842604Phase 3Results posted
- A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-WorldCompletedNCT04337138Results posted
- A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT03416179Phase 3Results posted
- A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid LeukemiaTerminatedNCT02954653Phase 1Results posted
- Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT02785900Phase 3Results posted
- A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML PatientsTerminatedNCT02614560Phase 1/2Results posted
- A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML PatientsCompletedNCT02367456Phase 1Results posted
- A Study Of PF-04449913 In Japanese Patients With Select Hematologic MalignanciesCompletedNCT02038777Phase 1Results posted
- MEK162 for Patients With RAS/RAF/MEK Activated TumorsCompletedNCT01885195Phase 2Results posted
- A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01546038Phase 2Results posted
- Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous MalignanciesCompletedNCT01461538Phase 2Results posted
- AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)CompletedNCT00071006Phase 2Results posted
- Acute Myeloid Leukemia Real World Treatment PatternsWithdrawnNCT04230564
- A Safety Study of SEA-CD70 in Patients With Myeloid MalignanciesActive, not recruitingNCT04227847Phase 1
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaTerminatedNCT03530683Phase 1
- A Safety Study of SGN-CD123A in Patients With Acute Myeloid LeukemiaTerminatedNCT02848248Phase 1
- A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AMLCompletedNCT02326584Phase 1
- Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative TherapyNo longer availableNCT02312037
- A Safety Study of SGN-CD33A in AML PatientsCompletedNCT01902329Phase 1
- Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological MalignanciesCompletedNCT01399840Phase 1
- Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular RemissionCompletedNCT00962767Phase 3
- A Study of ARRY-520 in Patients With Advanced Myeloid LeukemiaCompletedNCT00637052Phase 1/2
- A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AMLCompletedNCT00528333Phase 2
- Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With LeukemiaCompletedNCT00304447Phase 4
- A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT00283114Phase 1
- Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual CareCompletedNCT00161668
- Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell TransplantCompletedNCT00044733Phase 2
- Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid LeukemiaCompletedNCT00037596Phase 2
- Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid LeukemiaCompletedNCT00037583Phase 2
- CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First RelapseCompletedNCT00003673Phase 2
- CMA-676 in Treating Patients With Acute Myeloid Leukemia in First RelapseCompletedNCT00003131Phase 2